Professional Documents
Culture Documents
Sr. No Molecule Name ONCOLOGY PRODUCTS 1 2 3 4 5 6 TEMOZOLOMIDE* CAPECITABINE IMATINIB PEMETREXED ERLOTINIB BORTEZOMIB STEROIDS 1 2 3 4 DUTASTERIDE NANDROLONE DECANOATE ROCURONIUM BROMIDE LOTEPREDNOL FERMENTATION PRODUCTS 1 HYALURONIC ACID OTHER PRODUCTS 1 ESZOPICLONE Sedative and Hypnotic Commercialized Ready Done Ready Osteoarthritis, Ophthalmic use Commercialized Ready Done BPH Product Hormonal, Anabolic Steroid Muscle Relaxant Corticosteroid for Ophthalmic use Commercialized Commercialized Commercialized Commercialized Ready Ready Ready Ready Done Done Done Done Ready Ready Ready Ready Antineoplastic Antineoplastic Antineoplastic Antineoplastic Antineoplastic Antineoplastic Commercialized Commercialized Commercialized Commercialized Commercialized Commercialized Ready Ready Ready Ready Ready Ready Done Done Done Done Done Done Ready Ready Ready Ready Ready August 2012 Therapeutic Category Development Priority Lab Samples Validation Batches DMF
* Product only available for offer in markets other than North America, Australia, Japan.
The above products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Reliance Life Sciences Private Limited offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.
P. T. O
Page No- 2 PHARMACEUTICAL FINISHED DOSAGE FORMS DEVELOPMENT LIST MAY 2012
Sr. No
Strength
Dosage Form
Therapeutic Category
Dossier
CAPECITABINE
150 mg and 500 mg 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg
Tablet
Antineoplastic
TEMOZOLOMIDE
Capsule
Antineoplastic
3 4
BORTEZOMIB PEMETREXED
Vial Vial
Antineoplastic Antineoplastic
The above products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Reliance Life Sciences Private Limited offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction.